Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial
Status:
Recruiting
Trial end date:
2021-03-28
Target enrollment:
Participant gender:
Summary
Patients with COVID-19 associated ARDS and mechanical ventilation have a high mortality. Part
of the disease is an activation of the coagulation system which seems to contribute to
clotformation in the pulmonary bloodstream. Recently we implemented an algorithm applying
higher doses of heparins (LMWH). However, this approach could not inhibit clotformation
enough. Bivalirudin could prevent clotformation better and support dissolving existing clots.
Therefore, we want to compare 50 patients with the standard treatment with 50 patients under
bivalirudin treatment which we normally apply in patients with a HIT-syndrome.
Our primary outcome measure is oxygenation reflected as P/F ratio.